{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:18:22Z","timestamp":1759940302540},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,8,29]],"date-time":"2012-08-29T00:00:00Z","timestamp":1346198400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s00198-012-2098-3","type":"journal-article","created":{"date-parts":[[2012,8,28]],"date-time":"2012-08-28T07:21:32Z","timestamp":1346138492000},"page":"1503-1511","source":"Crossref","is-referenced-by-count":13,"title":["Improved adherence with PTH(1\u201384) in an extension trial for 24\u00a0months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis"],"prefix":"10.1007","volume":"24","author":[{"given":"D. M.","family":"Black","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. L.","family":"Greenspan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"W\u00fcster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mu\u00f1oz-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. G.","family":"Bone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. J.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. S.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. A.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,8,29]]},"reference":[{"key":"2098_CR1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB (2007) Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326\u2013339","journal-title":"Ann Intern Med"},{"key":"2098_CR2","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"2098_CR3","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"2098_CR4","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"2098_CR5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"2098_CR6","first-page":"690","volume":"14","author":"DW Dempster","year":"1993","unstructured":"Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R (1993) Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690\u2013709","journal-title":"Endocr Rev"},{"key":"2098_CR7","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/jc.2009-1703","volume":"95","author":"JS Finkelstein","year":"2010","unstructured":"Finkelstein JS, Wyland JJ, Lee H, Neer RM (2010) Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 95:1838\u20131845","journal-title":"J Clin Endocrinol Metab"},{"key":"2098_CR8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0140-6736(06)69394-X","volume":"368","author":"JE Compston","year":"2006","unstructured":"Compston JE, Seeman E (2006) Compliance with osteoporosis therapy is the weakest link. Lancet 368:973\u2013974","journal-title":"Lancet"},{"key":"2098_CR9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","volume":"15","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003\u20131008","journal-title":"Osteoporos Int"},{"key":"2098_CR10","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","volume":"38","author":"KF Huybrechts","year":"2006","unstructured":"Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922\u2013928","journal-title":"Bone"},{"key":"2098_CR11","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013\u20131022","journal-title":"Mayo Clin Proc"},{"key":"2098_CR12","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s00198-006-0073-6","volume":"17","author":"M Rossini","year":"2006","unstructured":"Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914\u2013921","journal-title":"Osteoporos Int"},{"key":"2098_CR13","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00198-006-0179-x","volume":"17","author":"D Weycker","year":"2006","unstructured":"Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645\u20131652","journal-title":"Osteoporos Int"},{"key":"2098_CR14","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00198-006-0171-5","volume":"17","author":"NK Arden","year":"2006","unstructured":"Arden NK, Earl S, Fisher DJ, Cooper C, Carruthers S, Goater M (2006) Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int 17:1626\u20131629","journal-title":"Osteoporos Int"},{"key":"2098_CR15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","volume":"353","author":"DM Black","year":"2005","unstructured":"Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555\u2013565","journal-title":"N Engl J Med"},{"key":"2098_CR16","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207\u20131215","journal-title":"N Engl J Med"},{"key":"2098_CR17","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1210\/jc.2003-030768","volume":"88","author":"AB Hodsman","year":"2003","unstructured":"Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R (2003) Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212\u20135220","journal-title":"J Clin Endocrinol Metab"},{"key":"2098_CR18","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/archinte.165.20.2414","volume":"165","author":"DH Solomon","year":"2005","unstructured":"Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414\u20132419","journal-title":"Arch Intern Med"},{"key":"2098_CR19","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","volume":"164","author":"R Lindsay","year":"2004","unstructured":"Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164:2024\u20132030","journal-title":"Arch Intern Med"},{"key":"2098_CR20","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346\u20133355","journal-title":"Arthritis Rheum"},{"key":"2098_CR21","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","volume":"23","author":"BM Obermayer-Pietsch","year":"2008","unstructured":"Obermayer-Pietsch BM, Marin F, McCloskey EV et al (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23:1591\u20131600","journal-title":"J Bone Miner Res"},{"key":"2098_CR22","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1185\/03007995.2010.524121","volume":"26","author":"JR Zanchetta","year":"2010","unstructured":"Zanchetta JR, Bogado CE, Cisari C, Aslanidis S, Greisen H, Fox J, Lems W (2010) Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36\u00a0months: treatment extension study. Curr Med Res Opin 26:2627\u20132633","journal-title":"Curr Med Res Opin"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-012-2098-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-012-2098-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-012-2098-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:08:48Z","timestamp":1558609728000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-012-2098-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,29]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["2098"],"URL":"https:\/\/doi.org\/10.1007\/s00198-012-2098-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,29]]}}}